2026 Q1 -tulosraportti
58 päivää sitten
‧1 t 1 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 6.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 t sitten · Muokattuhttps://forum.placera.se/inlagg/2b2ec452-581b-4b18-9665-4ecd4418cf54 On the Placera forum, a small debate is ongoing where BoBoKrull is not wrong. But a challenging question is posed. Thread starter Sado naturally means the obvious. That the Medicare application is imminent if one is to believe the Immunovia management. A news item is awaited that the application will be submitted, and that will be a nice milestone in itself. That should give the stock a small boost or perhaps a larger one. It is not meant that Medicare will give approval anytime soon, because it is a lengthy process. It is more lengthy there at Medicare than at New York, which can approve à la California-level anytime. Getting New York approved will provide a complete 50-state approval, and both these news items will make PancreaSure more attractive for a potential further partner discussion. And both these news items should, if (!) one can trust Immunovia management, happen now this summer. NY should have happened last month in June, but it has not happened. Medicare application submission was promised mid-2026, which we are at now. The ASSURE study is in place, and they will have ongoing updates on the study to Medicare, which was the plan we have been presented with. https://forum.placera.se/inlagg/2b2ec452-581b-4b18-9665-4ecd4418cf54- ·3 päivää sitten · MuokattuHi, a lot of good weather these days. Now we have reached mid-2026. That was when the medicare application was supposed to be submitted, right? Then it can't be many days into July before we see news about it, can it? If not, then they are not keeping the promise they made to us. How far can they stretch the rope and still call this mid-2026? ASSURE has already been talked about a bit not many weeks ago. Something that is necessary for the application that is to happen to medicare
15.6.But such a weak price movement in IMMNOV on day 2 of a news item. The pattern repeats itself for a stock that hasn't gained proper momentum previously (perhaps exceptions around the previous variant test and hyping? But then I wasn't even aware of the company. I was busy with completely different stocks at that time).- ·12.6.It's been an incredibly long time this stock has been "cheap" in light of expectations for business development. A bit difficult to understand, but the market is the market. One has probably been genuinely frightened before. I don't have any better explanation for this. One should probably expect that sometime in summer/autumn, big things will happen. But of course, the stock carries a certain risk here with a development company. The product development looks finished. Now several approvals and business development going forward remain.
- ·9.6. · MuokattuNews retrieved from AI: "Pancreatic Cancer Action Network (PanCAN) & Aignostics Partnership (June 9, 2026): Today, PanCAN announced a major partnership with AI-pathology company Aignostics. They will be applying advanced AI spatial profiling models to PanCAN's SPARK platform—one of the largest pancreatic cancer datasets in the world. While this does not involve Immunovia directly, industry analysts note that these types of deep-learning AI partnerships are rapidly accelerating the entire biomarker and liquid biopsy market, creating a strong tailwind for targeted early-detection blood tests like PancreaSure."
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
58 päivää sitten
‧1 t 1 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sitten · Muokattuhttps://forum.placera.se/inlagg/2b2ec452-581b-4b18-9665-4ecd4418cf54 On the Placera forum, a small debate is ongoing where BoBoKrull is not wrong. But a challenging question is posed. Thread starter Sado naturally means the obvious. That the Medicare application is imminent if one is to believe the Immunovia management. A news item is awaited that the application will be submitted, and that will be a nice milestone in itself. That should give the stock a small boost or perhaps a larger one. It is not meant that Medicare will give approval anytime soon, because it is a lengthy process. It is more lengthy there at Medicare than at New York, which can approve à la California-level anytime. Getting New York approved will provide a complete 50-state approval, and both these news items will make PancreaSure more attractive for a potential further partner discussion. And both these news items should, if (!) one can trust Immunovia management, happen now this summer. NY should have happened last month in June, but it has not happened. Medicare application submission was promised mid-2026, which we are at now. The ASSURE study is in place, and they will have ongoing updates on the study to Medicare, which was the plan we have been presented with. https://forum.placera.se/inlagg/2b2ec452-581b-4b18-9665-4ecd4418cf54
- ·3 päivää sitten · MuokattuHi, a lot of good weather these days. Now we have reached mid-2026. That was when the medicare application was supposed to be submitted, right? Then it can't be many days into July before we see news about it, can it? If not, then they are not keeping the promise they made to us. How far can they stretch the rope and still call this mid-2026? ASSURE has already been talked about a bit not many weeks ago. Something that is necessary for the application that is to happen to medicare
- 15.6.But such a weak price movement in IMMNOV on day 2 of a news item. The pattern repeats itself for a stock that hasn't gained proper momentum previously (perhaps exceptions around the previous variant test and hyping? But then I wasn't even aware of the company. I was busy with completely different stocks at that time).
- ·12.6.It's been an incredibly long time this stock has been "cheap" in light of expectations for business development. A bit difficult to understand, but the market is the market. One has probably been genuinely frightened before. I don't have any better explanation for this. One should probably expect that sometime in summer/autumn, big things will happen. But of course, the stock carries a certain risk here with a development company. The product development looks finished. Now several approvals and business development going forward remain.
- ·9.6. · MuokattuNews retrieved from AI: "Pancreatic Cancer Action Network (PanCAN) & Aignostics Partnership (June 9, 2026): Today, PanCAN announced a major partnership with AI-pathology company Aignostics. They will be applying advanced AI spatial profiling models to PanCAN's SPARK platform—one of the largest pancreatic cancer datasets in the world. While this does not involve Immunovia directly, industry analysts note that these types of deep-learning AI partnerships are rapidly accelerating the entire biomarker and liquid biopsy market, creating a strong tailwind for targeted early-detection blood tests like PancreaSure."
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 6.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 |
2026 Q1 -tulosraportti
58 päivää sitten
‧1 t 1 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 6.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sitten · Muokattuhttps://forum.placera.se/inlagg/2b2ec452-581b-4b18-9665-4ecd4418cf54 On the Placera forum, a small debate is ongoing where BoBoKrull is not wrong. But a challenging question is posed. Thread starter Sado naturally means the obvious. That the Medicare application is imminent if one is to believe the Immunovia management. A news item is awaited that the application will be submitted, and that will be a nice milestone in itself. That should give the stock a small boost or perhaps a larger one. It is not meant that Medicare will give approval anytime soon, because it is a lengthy process. It is more lengthy there at Medicare than at New York, which can approve à la California-level anytime. Getting New York approved will provide a complete 50-state approval, and both these news items will make PancreaSure more attractive for a potential further partner discussion. And both these news items should, if (!) one can trust Immunovia management, happen now this summer. NY should have happened last month in June, but it has not happened. Medicare application submission was promised mid-2026, which we are at now. The ASSURE study is in place, and they will have ongoing updates on the study to Medicare, which was the plan we have been presented with. https://forum.placera.se/inlagg/2b2ec452-581b-4b18-9665-4ecd4418cf54
- ·3 päivää sitten · MuokattuHi, a lot of good weather these days. Now we have reached mid-2026. That was when the medicare application was supposed to be submitted, right? Then it can't be many days into July before we see news about it, can it? If not, then they are not keeping the promise they made to us. How far can they stretch the rope and still call this mid-2026? ASSURE has already been talked about a bit not many weeks ago. Something that is necessary for the application that is to happen to medicare
- 15.6.But such a weak price movement in IMMNOV on day 2 of a news item. The pattern repeats itself for a stock that hasn't gained proper momentum previously (perhaps exceptions around the previous variant test and hyping? But then I wasn't even aware of the company. I was busy with completely different stocks at that time).
- ·12.6.It's been an incredibly long time this stock has been "cheap" in light of expectations for business development. A bit difficult to understand, but the market is the market. One has probably been genuinely frightened before. I don't have any better explanation for this. One should probably expect that sometime in summer/autumn, big things will happen. But of course, the stock carries a certain risk here with a development company. The product development looks finished. Now several approvals and business development going forward remain.
- ·9.6. · MuokattuNews retrieved from AI: "Pancreatic Cancer Action Network (PanCAN) & Aignostics Partnership (June 9, 2026): Today, PanCAN announced a major partnership with AI-pathology company Aignostics. They will be applying advanced AI spatial profiling models to PanCAN's SPARK platform—one of the largest pancreatic cancer datasets in the world. While this does not involve Immunovia directly, industry analysts note that these types of deep-learning AI partnerships are rapidly accelerating the entire biomarker and liquid biopsy market, creating a strong tailwind for targeted early-detection blood tests like PancreaSure."
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt